Surrozen (NASDAQ:SRZN – Get Free Report) and Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.
Volatility & Risk
Surrozen has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.
Profitability
This table compares Surrozen and Halozyme Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Surrozen | -2,885.33% | N/A | -93.62% |
| Halozyme Therapeutics | 24.86% | 260.98% | 23.91% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Surrozen | 1 | 1 | 4 | 1 | 2.71 |
| Halozyme Therapeutics | 1 | 3 | 9 | 0 | 2.62 |
Surrozen currently has a consensus target price of $48.33, indicating a potential upside of 64.85%. Halozyme Therapeutics has a consensus target price of $91.20, indicating a potential downside of 16.99%. Given Surrozen’s stronger consensus rating and higher possible upside, equities analysts clearly believe Surrozen is more favorable than Halozyme Therapeutics.
Valuation and Earnings
This table compares Surrozen and Halozyme Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Surrozen | $3.48 million | 97.82 | -$242.03 million | ($40.55) | -0.72 |
| Halozyme Therapeutics | $1.40 billion | 8.93 | $316.89 million | $3.35 | 32.79 |
Halozyme Therapeutics has higher revenue and earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
66.6% of Surrozen shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Halozyme Therapeutics beats Surrozen on 10 of the 15 factors compared between the two stocks.
About Surrozen
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
